1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Lymphoma - Pipeline Review, H2 2013

Lymphoma - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 206 pages

Lymphoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lymphoma.
- A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lymphoma - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Lymphoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Lymphoma 13
Lymphoma Therapeutics under Development by Companies 15
Lymphoma Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Lymphoma Therapeutics - Products under Development by Companies 32
Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 45
Companies Involved in Lymphoma Therapeutics Development 47
Bristol-Myers Squibb Company 47
Genzyme Corporation 48
DURECT Corporation 49
Kyowa Hakko Kirin Co., Ltd. 50
Biogen Idec Inc. 51
Allergan, Inc. 52
Shionogi and Co., Ltd. 53
Sanofi-Aventis 54
AstraZeneca PLC 55
BioDelivery Sciences International, Inc. 56
Nektar Therapeutics 57
MedImmune LLC 58
Quark Pharmaceuticals, Inc. 59
Daiichi Sankyo Company, Ltd 60
Merck and Co., Inc. 61
Dainippon Sumitomo Pharma Co., Ltd. 62
Sangamo BioSciences, Inc. 63
XenoPort, Inc. 64
BioLineRx, Ltd. 65
Samyang Corporation 66
Acorda Therapeutics, Inc. 67
Astellas Pharma Inc. 68
Daewoong Pharmaceutical Co., Ltd. 69
Dong-A Pharmaceutical Co., Ltd. 70
Esteve Group 71
Glenmark Pharmaceuticals Ltd. 72
Laboratoires Pierre Fabre SA 73
LEO Pharma A/S 74
Pfizer Inc. 75
Sigma-Tau S.p.A. 76
Teva Pharmaceutical Industries Limited 77
Sun Pharmaceutical Industries Limited 78
Vernalis plc 79
Merck KGaA 80
EpiCept Corporation 81
Evotec Aktiengesellschaft 82
GW Pharmaceuticals plc 83
Anavex Life Sciences Corp. 84
IntelGenx Technologies Corp. 85
AVANIR Pharmaceuticals 86
Lpath, Inc. 87
Medivir AB 88
Benitec Ltd. 89
Bionomics Limited 90
Nuvo Research Inc. 91
CombinatoRx, Incorporated 92
Torrent Pharmaceuticals Limited 93
KunWha Pharmaceutical Co., Ltd. 94
Diamyd Medical AB 95
Transition Therapeutics Inc. 96
Neurim Pharmaceuticals (1991) Ltd. 97
Pluristem Therapeutics Inc. 98
DARA BioSciences, Inc. 99
Newron Pharmaceuticals S.p.A. 100
Debiopharm Group 101
Auspex Pharmaceuticals 102
VistaGen Therapeutics , Inc. 103
Palau Pharma S.A 104
Snowdon Inc. 105
Neurotune AG 106
Grunenthal GmbH 107
Xenon Pharmaceuticals Inc. 108
Amura Holdings Ltd. 109
Affectis Pharmaceuticals AG 110
AngioChem Inc. 111
PharmEste 112
Trevena, Inc. 113
Arcion Therapeutics, Inc. 114
GP Pharm, S.A. 115
Kineta, Inc. 116
WEX Pharmaceuticals Inc. 117
Hydra Biosciences, Inc. 118
Yaupon Therapeutics, Inc. 119
NeurAxon, Inc. 120
Virobay Inc. 121
Concert Pharmaceuticals, Inc. 122
Knopp Neurosciences Inc. 123
QRxPharma Limited 124
Cara Therapeutics, Inc. 125
Targacept, Inc. 126
Intellipharmaceutics International Inc. 127
KYORIN Pharmaceutical Co., Ltd. 128
to-BBB technologies BV 129
Lipopharma 130
Winston Pharmaceuticals, Inc. 131
Medisyn Technologies, Inc. 132
Maruho Co.,Ltd. 133
NeuroTherapeutics Pharma Inc. 134
Bial - Portela and Ca, S.A. 135
CLL Pharma 136
Beijing Tide Pharmaceutical Co., Ltd. 137
Inserm Transfert SA 138
Spinifex Pharmaceuticals Pty Limited 139
TheraQuest Biosciences, LLC 140
MediProPharma, Inc. 141
Celtic Pharmaceutical Holdings L.P. 142
Vichem Chemie Research Ltd. 143
RaQualia Pharma Inc. 144
Naurex, Inc. 145
Cytogel Pharma, LLC 146
Lymphoma - Therapeutics Assessment 147
Assessment by Monotherapy Products 147
Assessment by Combination Products 148
Assessment by Route of Administration 149
Assessment by Molecule Type 151
Drug Profiles 153
pregabalin - Drug Profile 153
Product Description 153
Mechanism of Action 153
RandD Progress 153
nabiximols - Drug Profile 155
Product Description 155
Mechanism of Action 155
RandD Progress 155
capsaicin - Drug Profile 157
Product Description 157
Mechanism of Action 157
RandD Progress 157
capsaicin - Drug Profile 158
Product Description 158
Mechanism of Action 158
RandD Progress 158
buprenorphine hydrochloride - Drug Profile 159
Product Description 159
Mechanism of Action 159
RandD Progress 159
(gabapentin + thiamine + cobalamin) - Drug Profile 161
Product Description 161
Mechanism of Action 161
RandD Progress 161
Atx-08001 - Drug Profile 162
Product Description 162
Mechanism of Action 162
RandD Progress 162
eslicarbazepine acetate - Drug Profile 164
Product Description 164
Mechanism of Action 164
RandD Progress 164
minocycline - Drug Profile 166
Product Description 166
Mechanism of Action 166
RandD Progress 166
pregabalin CR - Drug Profile 167
Product Description 167
Mechanism of Action 167
RandD Progress 167
Lymphoma Therapeutics - Drug Profile Updates 168
Lymphoma Therapeutics - Discontinued Products 185
Lymphoma Therapeutics - Dormant Products 190
Lymphoma - Product Development Milestones 199
Featured News and Press Releases 199
Jul 08, 2013: Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 199
Jul 08, 2013: Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 199
Jul 01, 2013: Avanir Pharmaceuticals Announces Completion of Patient Enrollment in PRIME Study 200
Jun 28, 2013: Two New Formulations of E Keppra Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation 200
Jun 04, 2013: Zalicus Advancing Clinical Development Of Its Oral T-type Calcium Channel Blocker Z944 For Treatment Of Pain 201
May 23, 2013: Virobay Initiates Phase I Trial Of VBY-036 For Treatment Of Neuropathic Pain 201
May 10, 2013: Zalicus Presents Preclinical Data On T-type Calcium Channel Blocker Z160 At 32nd Annual Scientific Meeting Of American Pain Society 202
May 10, 2013: Zalicus Presents Preclinical Data On T-type Calcium Channel Blocker Z160 At 32nd Annual Scientific Meeting Of American Pain Society 202
Apr 23, 2013: Teva Pharma And Xenon Pharma Announce FDA Orphan Drug Designation For Pain Drug XEN402 203
Apr 23, 2013: Teva Pharma And Xenon Pharma Announce FDA Orphan Drug Designation For Pain Drug XEN402 204
Appendix 205
Methodology 205
Coverage 205
Secondary Research 205
Primary Research 205
Expert Panel Validation 205
Contact Us 206
Disclaimer 206



List of Tables

Number of Products Under Development for Lymphoma, H2 2013 13
Products under Development for Lymphoma - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Development by Companies, H2 2013 (Contd..2) 18
Number of Products under Development by Companies, H2 2013 (Contd..3) 19
Number of Products under Development by Companies, H2 2013 (Contd..4) 20
Number of Products under Development by Companies, H2 2013 (Contd..5) 21
Number of Products under Development by Companies, H2 2013 (Contd..6) 22
Number of Products under Development by Companies, H2 2013 (Contd..7) 23
Number of Products under Development by Companies, H2 2013 (Contd..8) 24
Number of Products under Investigation by Universities/Institutes, H2 2013 26
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 27
Comparative Analysis by Late Stage Development, H2 2013 28
Comparative Analysis by Mid Clinical Stage Development, H2 2013 29
Comparative Analysis by Early Clinical Stage Development, H2 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Development by Companies, H2 2013 (Contd..1) 33
Products under Development by Companies, H2 2013 (Contd..2) 34
Products under Development by Companies, H2 2013 (Contd..3) 35
Products under Development by Companies, H2 2013 (Contd..4) 36
Products under Development by Companies, H2 2013 (Contd..5) 37
Products under Development by Companies, H2 2013 (Contd..6) 38
Products under Development by Companies, H2 2013 (Contd..7) 39
Products under Development by Companies, H2 2013 (Contd..8) 40
Products under Development by Companies, H2 2013 (Contd..9) 41
Products under Development by Companies, H2 2013 (Contd..10) 42
Products under Development by Companies, H2 2013 (Contd..11) 43
Products under Development by Companies, H2 2013 (Contd..12) 44
Products under Investigation by Universities/Institutes, H2 2013 45
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 46
Bristol-Myers Squibb Company, H2 2013 47
Genzyme Corporation, H2 2013 48
DURECT Corporation, H2 2013 49
Kyowa Hakko Kirin Co., Ltd., H2 2013 50
Biogen Idec Inc., H2 2013 51
Allergan, Inc., H2 2013 52
Shionogi and Co., Ltd., H2 2013 53
Sanofi-Aventis, H2 2013 54
AstraZeneca PLC, H2 2013 55
BioDelivery Sciences International, Inc., H2 2013 56
Nektar Therapeutics, H2 2013 57
MedImmune LLC, H2 2013 58
Quark Pharmaceuticals, Inc., H2 2013 59
Daiichi Sankyo Company, Ltd, H2 2013 60
Merck and Co., Inc., H2 2013 61
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 62
Sangamo BioSciences, Inc., H2 2013 63
XenoPort, Inc., H2 2013 64
BioLineRx, Ltd., H2 2013 65
Samyang Corporation, H2 2013 66
Acorda Therapeutics, Inc., H2 2013 67
Astellas Pharma Inc., H2 2013 68
Daewoong Pharmaceutical Co., Ltd., H2 2013 69
Dong-A Pharmaceutical Co., Ltd., H2 2013 70
Esteve Group, H2 2013 71
Glenmark Pharmaceuticals Ltd., H2 2013 72
Laboratoires Pierre Fabre SA, H2 2013 73
LEO Pharma A/S, H2 2013 74
Pfizer Inc., H2 2013 75
Sigma-Tau S.p.A., H2 2013 76
Teva Pharmaceutical Industries Limited, H2 2013 77
Sun Pharmaceutical Industries Limited, H2 2013 78
Vernalis plc, H2 2013 79
Merck KGaA, H2 2013 80
EpiCept Corporation, H2 2013 81
Evotec Aktiengesellschaft, H2 2013 82
GW Pharmaceuticals plc, H2 2013 83
Anavex Life Sciences Corp., H2 2013 84
IntelGenx Technologies Corp., H2 2013 85
AVANIR Pharmaceuticals, H2 2013 86
Lpath, Inc., H2 2013 87
Medivir AB, H2 2013 88
Benitec Ltd., H2 2013 89
Bionomics Limited, H2 2013 90
Nuvo Research Inc., H2 2013 91
CombinatoRx, Incorporated, H2 2013 92
Torrent Pharmaceuticals Limited, H2 2013 93
KunWha Pharmaceutical Co., Ltd., H2 2013 94
Diamyd Medical AB, H2 2013 95
Transition Therapeutics Inc., H2 2013 96
Neurim Pharmaceuticals (1991) Ltd., H2 2013 97
Pluristem Therapeutics Inc., H2 2013 98
DARA BioSciences, Inc., H2 2013 99
Newron Pharmaceuticals S.p.A., H2 2013 100
Debiopharm Group, H2 2013 101
Auspex Pharmaceuticals, H2 2013 102
VistaGen Therapeutics , Inc., H2 2013 103
Palau Pharma S.A, H2 2013 104
Snowdon Inc., H2 2013 105
Neurotune AG, H2 2013 106
Grunenthal GmbH, H2 2013 107
Xenon Pharmaceuticals Inc., H2 2013 108
Amura Holdings Ltd., H2 2013 109
Affectis Pharmaceuticals AG, H2 2013 110
AngioChem Inc., H2 2013 111
PharmEste, H2 2013 112
Trevena, Inc., H2 2013 113
Arcion Therapeutics, Inc., H2 2013 114
GP Pharm, S.A., H2 2013 115
Kineta, Inc., H2 2013 116
WEX Pharmaceuticals Inc., H2 2013 117
Hydra Biosciences, Inc., H2 2013 118
Yaupon Therapeutics, Inc., H2 2013 119
NeurAxon, Inc., H2 2013 120
Virobay Inc., H2 2013 121
Concert Pharmaceuticals, Inc., H2 2013 122
Knopp Neurosciences Inc., H2 2013 123
QRxPharma Limited, H2 2013 124
Cara Therapeutics, Inc., H2 2013 125
Targacept, Inc., H2 2013 126
Intellipharmaceutics International Inc., H2 2013 127
KYORIN Pharmaceutical Co., Ltd., H2 2013 128
to-BBB technologies BV, H2 2013 129
Lipopharma, H2 2013 130
Winston Pharmaceuticals, Inc., H2 2013 131
Medisyn Technologies, Inc., H2 2013 132
Maruho Co.,Ltd., H2 2013 133
NeuroTherapeutics Pharma Inc., H2 2013 134
Bial - Portela and Ca, S.A., H2 2013 135
CLL Pharma, H2 2013 136
Beijing Tide Pharmaceutical Co., Ltd., H2 2013 137
Inserm Transfert SA, H2 2013 138
Spinifex Pharmaceuticals Pty Limited, H2 2013 139
TheraQuest Biosciences, LLC, H2 2013 140
MediProPharma, Inc., H2 2013 141
Celtic Pharmaceutical Holdings L.P., H2 2013 142
Vichem Chemie Research Ltd., H2 2013 143
RaQualia Pharma Inc., H2 2013 144
Naurex, Inc., H2 2013 145
Cytogel Pharma, LLC, H2 2013 146
Assessment by Monotherapy Products, H2 2013 147
Assessment by Combination Products, H2 2013 148
Assessment by Stage and Route of Administration, H2 2013 150
Assessment by Stage and Molecule Type, H2 2013 152
Lymphoma Therapeutics - Drug Profile Updates 168
Lymphoma Therapeutics - Discontinued Products 185
Lymphoma Therapeutics - Discontinued Products (Contd..1) 186
Lymphoma Therapeutics - Discontinued Products (Contd..2) 187
Lymphoma Therapeutics - Discontinued Products (Contd..3) 188
Lymphoma Therapeutics - Discontinued Products (Contd..4) 189
Lymphoma Therapeutics - Dormant Products 190
Lymphoma Therapeutics - Dormant Products (Contd..1) 191
Lymphoma Therapeutics - Dormant Products (Contd..2) 192
Lymphoma Therapeutics - Dormant Products (Contd..3) 193
Lymphoma Therapeutics - Dormant Products (Contd..4) 194
Lymphoma Therapeutics - Dormant Products (Contd..5) 195
Lymphoma Therapeutics - Dormant Products (Contd..6) 196
Lymphoma Therapeutics - Dormant Products (Contd..7) 197
Lymphoma Therapeutics - Dormant Products (Contd..8) 198



List of Figures

Number of Products under Development for Lymphoma, H2 2013 13
Products under Development for Lymphoma - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 25
Late Stage Products, H2 2013 28
Mid Clinical Stage Products, H2 2013 29
Early Clinical Stage Products, H2 2013 30
Discovery and Pre-Clinical Stage Products, H2 2013 31
Assessment by Monotherapy Products, H2 2013 147
Assessment by Combination Products, H2 2013 148
Assessment by Route of Administration, H2 2013 149
Assessment by Stage and Route of Administration, H2 2013 150
Assessment by Molecule Type, H2 2013 151
Assessment by Stage and Molecule Type, H2 2013 152



Companies Mentioned

Bristol-Myers Squibb Company
Genzyme Corporation
DURECT Corporation
Kyowa Hakko Kirin Co., Ltd.
Biogen Idec Inc.
Allergan, Inc.
Shionogi and Co., Ltd.
Sanofi-Aventis
AstraZeneca PLC
BioDelivery Sciences International, Inc.
Nektar Therapeutics
MedImmune LLC
Quark Pharmaceuticals, Inc.
Daiichi Sankyo Company, Ltd
Merck and Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Sangamo BioSciences, Inc.
XenoPort, Inc.
BioLineRx, Ltd.
Samyang Corporation
Acorda Therapeutics, Inc.
Astellas Pharma Inc.
Daewoong Pharmaceutical Co., Ltd.
Dong-A Pharmaceutical Co., Ltd.
Esteve Group
Glenmark Pharmaceuticals Ltd.
Laboratoires Pierre Fabre SA
LEO Pharma A/S
Pfizer Inc.
Sigma-Tau S.p.A.
Teva Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
Vernalis plc
Merck KGaA
EpiCept Corporation
Evotec Aktiengesellschaft
GW Pharmaceuticals plc
Anavex Life Sciences Corp.
IntelGenx Technologies Corp.
AVANIR Pharmaceuticals
Lpath, Inc.
Medivir AB
Benitec Ltd.
Bionomics Limited
Nuvo Research Inc.
CombinatoRx, Incorporated
Torrent Pharmaceuticals Limited
KunWha Pharmaceutical Co., Ltd.
Diamyd Medical AB
Transition Therapeutics Inc.
Neurim Pharmaceuticals (1991) Ltd.
Pluristem Therapeutics Inc.
DARA BioSciences, Inc.
Newron Pharmaceuticals S.p.A.
Debiopharm Group
Auspex Pharmaceuticals
VistaGen Therapeutics , Inc.
Palau Pharma S.A
Snowdon Inc.
Neurotune AG
Grunenthal GmbH
Xenon Pharmaceuticals Inc.
Amura Holdings Ltd.
Affectis Pharmaceuticals AG
AngioChem Inc.
PharmEste
Trevena, Inc.
Arcion Therapeutics, Inc.
GP Pharm, S.A.
Kineta, Inc.
WEX Pharmaceuticals Inc.
Hydra Biosciences, Inc.
Yaupon Therapeutics, Inc.
NeurAxon, Inc.
Virobay Inc.
Concert Pharmaceuticals, Inc.
Knopp Neurosciences Inc.
QRxPharma Limited
Cara Therapeutics, Inc.
Targacept, Inc.
Intellipharmaceutics International Inc.
KYORIN Pharmaceutical Co., Ltd.
to-BBB technologies BV
Lipopharma
Winston Pharmaceuticals, Inc.
Medisyn Technologies, Inc.
Maruho Co.,Ltd.
NeuroTherapeutics Pharma Inc.
Bial - Portela and Ca, S.A.
CLL Pharma
Beijing Tide Pharmaceutical Co., Ltd.
Inserm Transfert SA
Spinifex Pharmaceuticals Pty Limited
TheraQuest Biosciences, LLC
MediProPharma, Inc.
Celtic Pharmaceutical Holdings L.P.
Vichem Chemie Research Ltd.
RaQualia Pharma Inc.
Naurex, Inc.
Cytogel Pharma, LLC

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.